IDF21-0453 Phase-3 active control trial to evaluate Safety and Efficacy of Repaglinide plus Voglibose combination in T2D patients. (April 2022) - Chawla, M.S.; Sahoo, A.K.; Ramanathan, B.; Dhand, S.; Parikh, D.; Rathod, D.; Gupta, R.; Kavathiya, K.; Korukonda, K.